SCHEMBL8190867

SCHEMBL8190867

O=C(Cc1cccc(Br)c1)NCCc1ccc(OCc2ccccc2)c(OCc2ccccc2)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.55
KMT2A Q03164 3/20 0.55
MEN1 O00255 2/20 0.55
SMN1; SMN2 Q16637 2/20 0.54
POLB P06746 2/20 0.54
LMNA P02545 2/20 0.54
HTT P42858 1/20 0.54
MTNR1A P48039 2/20 0.53
MTNR1B P49286 2/20 0.53
HPGD P15428 1/20 0.50
SLC2A1 P11166 1/20 0.49
HDAC1 Q13547 1/20 0.48
HDAC2 Q92769 1/20 0.48
CA1 P00915 2/20 0.47
CA2 P00918 2/20 0.47
HSD17B2 P37059 1/20 0.47
NPC1 O15118 1/20 0.47
RAB9A P51151 1/20 0.47
ABCB1 P08183 1/20 0.46
ABCG2 Q9UNQ0 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8190937 0.91 ALDH1A1 (0.56) ALDH1A1KMT2AMEN1SMN1; SMN2POLB
SCHEMBL10604591 0.90 ALDH1A1 (0.61) ALDH1A1KMT2AMEN1SMN1; SMN2POLB
SCHEMBL14027267 0.85 ALDH1A1 (0.72) ALDH1A1KMT2AMEN1SMN1; SMN2POLB
SCHEMBL14027269 0.85 ALDH1A1 (0.72) ALDH1A1KMT2AMEN1SMN1; SMN2POLB
SCHEMBL18736058 0.85 MTNR1A (0.72) ALDH1A1KMT2AMEN1SMN1; SMN2POLB
SCHEMBL3542328 0.85 ALDH1A1 (0.57) ALDH1A1KMT2AMEN1SMN1; SMN2POLB
SCHEMBL6376361 0.84 ALDH1A1 (0.73) ALDH1A1KMT2AMEN1SMN1; SMN2POLB
SCHEMBL6376395 0.84 MTNR1A (0.71) ALDH1A1KMT2AMEN1SMN1; SMN2POLB
SCHEMBL6377560 0.84 ALDH1A1 (0.73) ALDH1A1KMT2AMEN1SMN1; SMN2POLB
SCHEMBL29944228 0.83 ALDH1A1 (0.56) ALDH1A1KMT2AMEN1SMN1; SMN2POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6043253-A TREATMENT OF DIABETES, OBESITY, LOWERING TRIGLYCERIDE OR CHOLESTEROL LEVELS, INCREASING HIGH DENSITY LIPOPROTEIN LEVELS OR DECREASING GUT MOTILITY, REDUCING NEUROGENIC INFLAMMATION, DEPRESSION OR GASTROINTESTINAL DISORDERS MERCK & CO., INC. (US) 2000-03-28 US disclosed